Vident Investment Advisory’s NovoCure NVCR Stock Holding History

Vident Investment Advisory’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,621	Closed	-$398K	–	1304
2023 Q1	$398K	Buy	6,621 +1,911	+41%	+$153K	0.01%	858
2022 Q4	$345K	Buy	4,710 +1,115	+31%	+$83.9K	0.01%	835
2022 Q3	$270K	Buy	+3,595	New	+$280K	0.01%	923
2022 Q1	–	Sell	-4,546	Closed	-$341K	–	1325
2021 Q4	$341K	Buy	4,546 +1,844	+68%	+$185K	0.01%	1028
2021 Q3	$314K	Buy	2,702 +1,133	+72%	+$171K	0.01%	993
2021 Q2	$348K	Sell	1,569 -824	-34%	-$160K	0.01%	915
2021 Q1	$316K	Sell	2,393 -149	-6%	-$23.6K	0.01%	904
2020 Q4	$440K	Buy	+2,542	New	+$348K	0.02%	754

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Vident Investment Advisory's NVCR Position: Q2 2023 in Review

Vident Investment Advisory sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 6,621 shares — an estimated $398K sold.

Vident Investment Advisory first reported a position in NVCR in Q4 2020 and held it in 8 quarters. The position peaked at $440K in Q4 2020. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

Vident Investment Advisory reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
Vident Investment Advisory sold 6,621 NovoCure shares in Q2 2023, an estimated $398K.
Vident Investment Advisory first reported a position in NovoCure in Q4 2020 and held it in 8 quarters.
Vident Investment Advisory's NovoCure position peaked at $440K in Q4 2020.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.